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We recently identified a new human subset of NK-like [KIR/NKG2A(+)] CD8(+) T cells 
with a marked/memory phenotype, high Eomesodermin expression, potent antigen-
independent cytotoxic activity, and the capacity to generate IFN-γ rapidly after exposure 
to pro-inflammatory cytokines. These features support the hypothesis that this new 
member of the innate T cell family in humans, hereafter referred to as innate CD8(+) 
T cells, has a role in cancer immune surveillance analogous to invariant natural killer 
T (iNKT) cells. Here, we report the first quantitative and functional analysis of innate 
CD8(+) T cells in a physiopathological context in humans, namely chronic myeloid 
leukemia (CML), a well-characterized myeloproliferative disorder. We have chosen 
CML based on our previous report that IL-4 production by iNKT cells was deficient 
in CML patients at diagnosis and considering the recent evidence in mice that IL-4 
promotes the generation/differentiation of innate CD8(+) T cells. We found that the 
pool of innate CD8(+) T cells was severely reduced in the blood of CML patients at 
diagnosis. Moreover, like iNKT and NK cells, innate CD8(+) T cells were functionally 
impaired, as attested by their loss of antigen-independent cytotoxic activity and IFN-γ 
production in response to innate-like stimulation with IL-12 +  IL-18. Remarkably, as 
previously reported for IL-4 production by iNKT cells, both quantitative and functional 
deficiencies of innate CD8(+) T cells were at least partially corrected in patients having 
achieved complete cytogenetic remission following tyrosine kinase inhibitor therapy. 
Finally, direct correlation between the functional potential of innate CD8(+) T and iNKT 
cells was found when considering all healthy donors and CML patients in diagnosis 
and remission, in accordance with the iNKT cell-dependent generation of innate 
CD8(+) T cells reported in mice. All in all, our data demonstrate that CML is associated 
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inTrODUcTiOn
A hallmark of the antigen-specific T lymphocytes of the adap-
tive immune system is their capacity to “remember” foreign 
pathogens long after they are first encountered. Indeed, as far 
as the CD8 T  cell pool is concerned, the main features that 
provide antigen-specific memory CD8(+) T cells with a protec-
tive advantage over naive CD8+ T cells are that memory CD8+ 
T cells persist for extended periods of time, are present in larger 
numbers, and respond more rapidly to foreign antigen than naive 
CD8(+) T cells do. However, studies in mice have provided clear 
evidence that some naive CD8(+) T cells can acquire the charac-
teristics and functions of memory CD8(+) T cells in the absence 
of foreign antigen encounters [reviewed in Ref. (1, 2)]. Such 
cells, hence called innate/memory CD8(+) T cells, may develop 
in response to alterations in the environment or the presence of 
high levels of the cytokine IL-4, and have also been identified in 
unmanipulated animals. A hallmark of innate/memory CD8(+) 
T cells is their marked NK-like/memory phenotype associated 
with pronounced expression of the transcription factor eomeso-
dermin (Eomes) (3, 4). Even though the actual physiological 
significance of innate/memory CD8(+) T cells remains to be 
established, these cells have enhanced response potential, includ-
ing the ability to efficiently combat pathogens (5, 6). Moreover, 
because these cells can rapidly produce large amounts of IFN-γ in 
response to innate-like stimulation by IL-12 + IL-18 (7, 8), they 
might contribute to the inflammation milieu during an early stage 
of immune response.
The existence of innate/memory CD8(+) T cells in mice 
raises the question whether an equivalent to these innate T cells 
exists in humans. Earlier studies identified a subset of CD8(+) 
T cells in human peripheral blood that express NK-cell receptors 
such as killer cell Ig-like receptors (KIRs) (9–11). We further 
demonstrated that the majority of KIR/NKG2A(+) CD8(+) 
T  cells have a memory phenotype and share functional and 
phenotypic features (12), see commentary (13): with innate/
memory T CD8(+) cells in mice (3, 4, 7, 8). Indeed, they express 
high levels of Eomes and display innate functions, such as cyto-
lytic capacity and rapid TCR-independent IFN-γ production in 
response to the innate cytokines IL-12 and IL-18. Regardless 
of their origin, KIR/NKG2A(+) Eomes(+) CD8(+) T cells 
harboring memory phenotype and innate-like functions have 
also been identified in human cord blood, suggesting that their 
development did not depend on cognate antigens. Additionally, 
the presence of these cells correlated well with expression of 
promyelocytic leukemia zinc finger (PLZF) among NKT cells 
in cord blood, a finding that is consistent with the hypothesis 
of a contribution of IL-4-producing, PLZF-expressing cells 
to their generation, as reported for their equivalents in mice 
(14, 15). These features validate the existence of a new member 
of the innate T cell family in humans, which we have termed 
innate CD8(+) T cells. However, to date, even though evidence 
accounts for their potential physiological relevance, whether 
innate CD8(+) T cells can mediate potent immunity in humans 
remains to be investigated.
Chronic myeloid leukemia (CML) is a well-characterized 
myeloproliferative disorder, which results from dysregulated 
tyrosine kinase (TK) activity of the fusion oncoprotein BCR-
ABL (16). Imatinib mesylate (IM), a competitive inhibitor of the 
BCR-ABL TK activity, is currently used as a first-line therapy for 
newly diagnosed patients in the chronic phase (CML-CP) (17). 
Overall, TK inhibitor (TKI) therapies have led to deep molecular 
responses in CML, dramatically improved life expectancy, and 
more recently, successful treatment-free survival has become a 
new goal (18). However, a significant proportion of patients will 
not fulfill the conditions allowing for treatment discontinuation 
while more than 40% of those eligible for treatment discontinu-
ation relapse during the first 6  months after therapy cessation. 
Additional therapeutic strategies aiming at a potentiation and/
or restoration of immune antitumor functions, therefore, remain 
a main avenue of research, which may be helpful in long-term 
control of CML.
A sizable number of clinical and experimental data underscore 
the dysregulation of innate immune components in CML. These 
regulatory elements comprise dendritic cells (19), NK cells (20, 
21), and invariant natural killer T (iNKT) cells (22), an innate 
T cell subset co-expressing activated/memory and NK mark-
ers, which is well-recognized for its antitumor activity (23–26). 
In  accordance with this notion, we recently reported CML 
immune subversion of iNKT-cell activities in CML patients at 
diagnosis (22, 27), including reduced or suppressed expression 
of perforin, CD95L, and (PLZF), a transcription factor required 
for maintenance of iNKT cell functions (28, 29). Remarkably, 
these functional deficiencies were shown to have been partially 
repaired in patients having achieved complete cytogenetic remis-
sion (CCyR) following TKI therapy (22).
In mice, IL-4-producing/PLZF-expressing cells, including 
iNKT cell, have been demonstrated to regulate the generation 
of innate/memory CD8(+) T cells (14, 15). Considering the 
functional deficiencies of iNKT cells in CML-CP patients at 
diagnosis and the fact that IL-4 production by iNKT cells was 
partially restored in patients having achieved CCyR after TKI 
therapy (22), we surmised that innate CD8(+) T cells might also 
be altered during CML and be restored in CML patients with 
CCyR. We further attempted to correlate the presence of innate 
CD8(+) T cells with that of iNKT cells to estimate the possible 
implication in humans of the peripheral iNKT cell pool in the 
development of its CD8(+) T-cell counterpart.
with deficiencies of innate CD8(+) T cells that are restored upon remission, thereby 
suggesting their possible contribution to disease control. More generally, our study 
strongly supports the existence of an innate iNKT/innate CD8(+) T-cell axis in humans 
and reveals its potential contribution to the restoration of tumor immune surveillance.
Keywords: innate cD8(+) T cells, nK-like cD8(+) T cells, inKT cells, chronic myeloid leukemia, tyrosine kinase inhibitor
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MaTerials anD MeThODs
Peripheral Blood Mononuclear cells 
(PBMcs)
Venous blood from CML-CP patients at diagnosis or having 
achieved a major molecular response and currently treated with 
IM (CML-IM) was collected on heparin (Oncology-Hematology 
Department, Poitiers, France). All patients gave informed consent 
in accordance with the Declaration of Helsinki for participation 
in the study, which was approved by the scientific committee of 
the INSERM CIC-1402 (Poitiers, France). Healthy donors (HDs) 
were volunteers from the Pôle Biologie Santé (Poitiers, France). 
PBMCs were isolated from blood samples by density gradient 
centrifugation (Histopaque®-1077, Sigma-Aldrich), resuspended 
in 90% fetal calf serum with 10% DMSO, and placed in a con-
trolled rate freezer for cryopreservation at −80°C until use.
cell culture and Functional assays
All cell cultures (1 ×  106  cells/mL) were performed in RPMI 
1640 medium supplemented with 10% heat-inactivated FCS and 
antibiotics. For IL-12  +  IL-18 stimulation, PBMCs from HD 
or CML patients were seeded at 1 ×  106  cells/mL into 24-well 
plates and incubated for 48  h with 20  ng/mL of each cytokine 
(R&D Systems). Golgistop (BD Biosciences) was added for the 
last 5 h of culture. CD107a degranulation assays were performed 
as previously described (12). Briefly, PBMCs were seeded into 
96-well round (U) bottom culture plates, preincubated for 48 h 
with IL-15 (20 ng/mL, R&D Systems) prior to CD16 triggering, 
and Golgistop (BD Biosciences) was added in the last 4  h of 
culture. For IL-4 stimulation, PBMCs from HDs were seeded at 
0.5 × 106 cells/mL into 24-well plates and incubated for 7 days 
with 20 ng/mL of recombinant human IL-4 (R&D Systems).
Flow cytometry
Phenotypic analysis of PBMCs was performed by flow cytometry 
either ex vivo or after culture. Expression of different markers 
was assessed by staining with appropriate combinations of the 
following antibodies (mAbs): anti-CD3 BV421 (clone: UCHT1, 
BioLegend), anti-CD8 PE-Cy7 (clone: RPA-T8, Biolegend), anti-
IFN-γ FITC (clone: B27, BioLegend), anti-perforin FITC (clone: 
δG9, BD Biosciences), anti-TCR Vα24-Jα18 APC (clone: 6B11, 
Biolegend), anti-CD107a FITC (clone H4A3, BD Biosciences), 
anti-Eomes eFluor® 660 (clone: WD1928, eBiosciences), and 
anti-PLZF PE (clone: Mags.21F7, eBioscience). Pan-KIR/NKG2A 
referred to staining with the mix of the three following antibod-
ies from Miltenyi Biotech: anti-KIR2D PE (clone: NKVFS1), 
anti-KIR3DL1/KIR3DL2 (CD158e/k) PE (clone: 5.133), and 
anti-NKG2A (CD159a) PE (clone: REA110). Dead cells were 
excluded by using the Live/Dead® Fixable Near-IR Dead Cell 
Stain kit (Life Technologies). For nuclear Eomes or PLZF stain-
ing and intracytoplasmic IFN-γ or perforin staining, cells were 
permeabilized with an anti-human Foxp3 staining kit (eBiosci-
ence) and a Cytofix/Cytoperm kit (BD Biosciences), respectively. 
Cells were analyzed by eight-color flow cytometry (FACSVerse™ 
cytometer and FACSuite™ software, BD Biosciences) and were 
analyzed using FlowJo v10 (TreeStar, Inc.). Innate CD8(+) T cells 
are defined as CD3(+) CD8(+) Eomes(+) KIR/NKG2A(+) and 
iNKT cells as CD3(+) TCRVα24-Jα18(+)-expressing cells after 
gating on live PBMCs.
statistical analysis
Statistical analyses were performed using GraphPad Prism 
version 6.0 (GraphPad Software). The statistical significance of 
differences in mean values was analyzed by the Mann–Whitney 
or Wilcoxon non-parametric test. The correlation Spearman test 
was used to test the association between the ranked variables 
Eomes and PLZF. Results were considered to be statistically 
significant when p < 0.05.
resUlTs
Quantitative and Functional Deficiencies 
of innate cD8(+) T cells from cMl-cP 
Patients
CD8(+) T cells co-expressing Eomes and KIR/NKG2A represent 
a new, functionally distinct “innate” subset in humans, with 
potential antitumor activities (12, 13). Based on our evidence 
for CML immune subversion of iNKT-cell activities (22, 27), we 
first investigated possible dysfunctions of this new innate CD8 
T subset (for gating strategy, see Figure 1A) in CML patients at 
diagnosis (CML-CP). As depicted in Figure 1B, the frequency of 
KIR/NKG2A(+) Eomes(+) CD8(+) T cells was more than 2.5-
fold lower in CML-CP patients (3.1% ± 0.7; n = 6) than in HDs 
(8.2% ± 0.9; n = 15).
Note that both the proportion of cells expressing Eomes 
among the KIR/NKG2A(+) CD8(+) T cell subset (Figure S1 in 
Supplementary Material) and the expression levels (Figure 1C) 
were significantly reduced in CML-CP patients [frequency: 
26.3% ±  3.2 (n =  6) and mean fluorescence intensity (MFI): 
2.17 ±  0.25 (n =  6), respectively] as compared to HD [fre-
quency: 46.5% ± 4.6 (n = 14) and MFI: 3.95 ± 0.52 (n = 15), 
respectively]. Taken together, these data are consistent with 
impaired differentiation of the innate CD8 T cell subset in 
CML-CP patients.
We have previously reported (12) and have confirmed in 
our present HD cohort (Figure  2A) that the rapid production 
of IFN-γ in response to innate-like stimulation by IL-12 + IL-18 
constitutes a unique hallmark of innate CD8(+) T cells. Indeed, 
this functional reactivity to IL-12 + IL-18 was found in the innate 
KIR/NKG2A(+) Eomes(+) fraction (24.8% ± 1.2; n = 6) and not 
in the conventional/memory KIR/NKG2A(−) Eomes(+) pools of 
CD8(+) T cells (1.4% ± 0.8; n = 6).
Remarkably, this function was not maintained in innate 
CD8(+) T cells from CML-CP patients, in which IL-12 + IL-18-
induced intracellular IFN-γ expression was virtually undetectable 
[0.7% ± 0.1 (n = 6) vs. 0.4% ± 0.02 (n = 5) in their conventional/
memory counterpart], as compared with HD (24.8%  ±  1.2 
(n =  6) vs. 1.4% ±  0.8 (n =  6) in their conventional/memory 
counterpart) (Figure 2A). In HD, innate CD8(+) T cells express 
more cytolytic activity than does their conventional/memory 
[KIR/NKG2A(−) Eomes(+)] CD8(+) counterpart, as attested by 
their more elevated perforin expression [71.4% ±  5.3 (n =  10) 
FigUre 1 | chronic myeloid leukemia (cMl)-cP is associated with acquired quantitative defects of innate cD8(+) T cells. (a) Gating strategy. Eomes 
and killer cell Ig-like receptor (KIR)/NKG2A expression among peripheral blood mononuclear cells was analyzed by flow cytometry after gating on live cells 
(Near-IR) and then on CD8(+) CD3(+) populations. Quantile contour plots show one representative sample for each group of healthy donor (HD) or CML-CP 
patients. Solid and dotted lines on histograms represent Eomes or pan-KIR/NKG2A expression or isotype control, respectively. (B) Decreased innate CD8(+) T cell 
counts in CML-CP patients. Frequency (mean ± SEM) of KIR/NKG2A(+) Eomes(+) cells among total CD8(+) CD3(+) cells in HD and CML-CP patients. Each dot 
represents one HD or CML-CP patient. (c) Decreased Eomes expression in CD3(+) CD8(+) KIR/NKG2A(+) T cells in CML-CP patients. Mean fluorescence intensity 
(MFI) of Eomes expression (mean ± SEM) in KIR/NKG2A(+) CD8(+) T cells from HD and CML-CP patients were analyzed after gating on KIR/NKG2A(+) CD8(+) 
CD3(+) cells. MFI of Eomes expression was normalized on MFI of Eomes from total KIR/NKG2A(−) CD3(−) cells. Statistical significance was determined by the 
two-tailed Mann–Whitney non-parametric test. *p < 0.05; **p < 0.01.
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and 42.4% ± 9.1 (n = 6), respectively] (Figure 2B), and natural 
antibody-dependent cytotoxicity through CD16 as a lysis recep-
tor [26.4% ± 6.2 (n = 6) and 11.4% ± 3.5 (n = 6), respectively] 
(Figure 2C).
As for intracellular IFN-γ expression, these two functions 
were once again dramatically reduced in innate CD8(+) T cells 
from CML-CP patients [44.0 ±  6.7% (n =  10) and 6.8% ±  4.1 
(n =  5), respectively] all the way down to the levels found in 
the conventional/memory population [26% ±  13 (n =  6) and 
5.1% ± 1.9 (n = 5), respectively] (Figures 2B,C).
Finally, both IFN-γ after IL-12  +  IL-18 stimulation and 
cytolytic activity of classical NK cells were likewise decreased in 
CML-CP patients [7.0% ± 2.0 (n = 8) and 34.3% ± 11.5 (n = 5), 
respectively] as compared to HD [25.8% ±  3.9 (n =  15) and 
65.9% ± 8.1 (n = 6), respectively] (Figure S2 in Supplementary 
Material). These findings, together with the similar frequencies of 
IFN-γ-expressing innate CD8(+) T cells, upon TCR engagement 
in HD (7.8% ± 6.4; n = 7) and CML-CP patients (9.1% ± 2.3; 
n = 7) (Figure S3 in Supplementary Material), would appear to 
imply that the functional deficiencies of innate CD8(+) T cells 
in CML-CP patients affect innate rather than adaptive immune 
responses.
Partial correction of Quantitative and 
Functional Deficiencies of innate cD8(+) 
T cells in Patients with ccyr
In patients having achieved complete cytogenetic remission 
following IM therapy, referred to as CML-IM patients, we 
observed a recovery of innate CD8(+) T cells (Figure 3A, left 
FigUre 2 | chronic myeloid leukemia (cMl)-cP is associated with 
acquired functional defects of innate cD 8(+) T cells. Peripheral blood 
mononuclear cells were cultured and stimulated for 48 h with IL-12 + IL-18 
(a,B) or IL-15 prior to CD16 triggering (c) (see Materials and Methods). IFN-γ 
(a), perforin (B) expression, or CD107a-expressing cells (c) (mean ± SEM) 
were analyzed after gating on killer cell Ig-like receptor (KIR)/NKG2A(+) 
Eomes(+) CD8(+) CD3(+) cells and KIR/NKG2A(−) Eomes(+) CD8(+) CD3(+) 
cells in healthy donor (HD) and CML-PC patients. Representative histograms 
of IFN-γ and perforin expression or CD107a-expressing cells are shown for 
KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) cells (filled line) or KIR/NKG2A(−) 
Eomes(+) CD8(+) CD3(+) cells (dotted line) for each group of HD and 
CML-CP patients. Without stimulation, frequency of IFN-γ expressing cells 
was lower than 0.1%. Full cohort data are shown. (a–c) Statistical 
significance to assess differences between populations in HD group or 
between HD and CML-CP was determined by the two-tailed Wilcoxon or 
Mann–Whitney non-parametric test, respectively. *p < 0.05; **p < 0.01.
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panel) in CML-IM patients (5.4% ± 0.5; n = 6 vs. 2.3% ± 0.6; 
n = 7 in CML-CP patients), back close to the proportions found 
in HD (7.8% ± 0.9; n = 16), while Eomes expression (Figure 3A, 
right panel) was increased in CML-IM patients (MFI: 2.5 ± 0.5; 
n = 6) as compared with CML-CP patients (1.4 ± 0.2; n = 7) and 
was partially restored relative to HD (MFI: 4.0 ± 0.5; n = 16). 
Accordingly, the proportion of cells expressing Eomes in the 
KIR/NKG2A(+) CD8 T cell subset was restored in CML-IM 
patients (42.7%  ±  2.9; n  =  6) as compared with CML-CP 
patients (26.3% ±  3.2; n =  6), reverting to the proportions 
found in HD (46.5% ± 4.6; n = 14) (Figure S1 in Supplementary 
Material).
Importantly, in these conditions, IFN-γ expression in 
response to IL-12 +  IL-18 was partially restored in the innate 
CD8(+) T cell compartment from CML-IM patients (7.7% ± 2.3; 
n =  6 vs. 0.7% ±  0.1; n =  5 in CML-CP patients) relative to 
HD (24.8% ±  1.2; n =  6) (Figure  3B), while cytolytic activity, 
measured as frequencies of CD107a-expressing cells in KIR/
NKG2A(+) Eomes(+) CD8(+) CD3(+) cells, returned to normal 
(27.3% ± 8.3; n = 6 vs. 6.8% ± 4.1; n = 5 in CML-CP patients), 
relative to HD (26.4% ± 6.2; n = 6) (Figure 3C).
Positive correlation between inKT cell 
PlZF expression and innate cD8(+)  
T cell eomes expression
We have previously reported that IL-4 production by iNKT 
cells returned to normal in patients having achieved complete 
CML remission with TKI therapy (22). Given that, in mice, 
the differentiation of innate CD8(+) T cells depends mainly 
on PLZF-expressing iNKT cells via their IL-4 production 
(14, 15); we reasoned that the same phenomenon might be 
applied to humans. In accordance with this notion, we found 
a significant positive correlation between the levels of Eomes 
in KIR/NKG2A(+) CD8(+) T cells and of PLZF in iNKT cells 
including all the HD, CML-CP, and CML-IM samples available 
(Figure 4A). Moreover, we found that after 7 days of culture in 
the presence of IL-4, recovery of CD8(+) T cells was slightly, but 
significantly, increased both in terms of frequency and numbers 
as compared to the total CD3(+) CD8(+) cells (Figures 4B,C). 
We also confirmed in humans that IL-4 strongly enhances Eomes 
expression both in total CD3(+) CD8(+) cells and in innate 
CD8(+) T cells (Figure 4D). Taken together, these findings sup-
port the possible involvement of iNKT cells through their IL-4 
production in the generation/maintaining of innate CD8(+) T 
cells in CML patients.
DiscUssiOn
Although the concept of innate memory CD8(+) T cells is now 
well established in mice, whether an equivalent T-cell population 
exists in humans remains under debate. We recently reported 
that CD8(+) T cells co-expressing Eomes and KIR/NKG2A 
may represent a new, functionally distinct innate T cell subset 
in humans. Here, by extending our study to CML, we report 
that this disease is associated with an acquired and reversible 
defect of innate CD8(+) T cells. To the best of our knowledge, 
FigUre 3 | The innate cD8 T cell subset is partially restored in 
patients having achieved complete cytogenetic remission with 
imatinib mesylate (iM) therapy. (a) Partial restoration of the pool of innate 
CD8(+) T cells in chronic myeloid leukemia (CML)-IM. Frequency 
(mean ± SEM) of killer cell Ig-like receptor (KIR)/NKG2A(+) Eomes(+) cells 
among total CD8(+) CD3(+) cells (left panel) in CML-CP and CML-IM patients. 
Dotted lines represent mean frequency values in healthy donor (HD). Mean 
fluorescence intensity (MFI) of Eomes expression (mean ± SEM, right panel) in 
KIR/NKG2A(+) CD8(+) T cells from CML-CP and CML-IM patients were 
analyzed after gating on KIR/NKG2A(+) CD8(+) CD3(+) cells. MFI of Eomes 
expression was normalized on MFI of Eomes from total KIR/NKG2A(−) 
CD3(−) cells. Dotted lines represent mean relative MFI Eomes values in HD. 
(B) Partial restoration of IL-12 + IL-18-induced IFN-γ expression by innate T 
CD8(+) cells from CML-IM patients. For details, see the caption of Figure 2a. 
Histograms represent frequencies (means ± SEM) of IFN-γ-expressing cells 
among KIR/NKG2A(+) Eomes(+) CD8(+) T cells after IL-12 + IL-18 
stimulation in each group of patients and HD. Without stimulation, frequency 
of IFN-γ-expressing cells was lower than 0.1%. (c) Complete restoration of 
natural cytotoxic activity by innate T CD8(+) cells from CML-IM patients. 
CD107a degranulation/expression after CD16 triggering (for details, see 
Section “Materials and Methods”) in KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) 
cells was analyzed by flow cytometry among peripheral blood mononuclear 
cells preincubated for 48 h with IL-15. Data (means ± SEM) are expressed as 
frequencies of CD107a-expressing cells in KIR/NKG2A(+) Eomes(+) CD8(+) 
CD3(+) cells from CML-CP and CML-IM patients. Dotted lines represent 
mean frequency values in HD. (a–c) Statistical significance was determined 
by the two-tailed Mann–Whitney non-parametric test (comparisons between 
HD and CML-CP patient groups) or the two-tailed Wilcoxon non-parametric 
test [comparisons between KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) cells 
and KIR/NKG2A(−) Eomes(+) CD8(+) CD3(+) cells from HD or CML-CP 
patient groups]. *p < 0.05; **p < 0.01.
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these findings are the first providing insights into the potential 
role of innate CD8(+) T cells in a physiopathological context in 
humans.
The finding that CML, at diagnosis is closely associated with 
a profound quantitative and functional deficiency in the innate 
CD8(+), T cell pool is in line with our hypothesis that this new 
subset may be involved during tumorigenesis in humans. This 
assumption was earlier based on our demonstration of termi-
nally differentiated effector features of innate CD8(+) T cells 
in humans, such as rapid production of IFN-γ and induction of 
cytolytic function upon stimulation in vitro. In the present study, 
our revelation of the profound impact of CML on these potential 
antitumoral functions of innate CD8(+) T cells, together with 
those of NK (see Figure S2 in Supplementary Material) and iNKT 
cells (22, 27), support a role in cancer immune surveillance of 
innate CD8(+) T cells analogous to the two other innate cell 
pools. Even though these findings corroborate the concept that 
innate CD8(+) T cells, like iNKT cells, may act against tumors 
in a TCR-independent and NK-like manner, the possibility that 
these cells recognize leukemia cells cannot be excluded and 
deserves further investigation.
Remarkably, deficiencies of innate CD8(+) T cells found at 
diagnosis in CML patients were significantly reversed upon 
remission following TKI therapy. These data are consistent with 
the hypothesis that reconstitution of the pool of innate CD8(+) 
T cells and its partial functional restoration together with those 
of NK cells and iNKT cells effectively contribute to disease 
control of CML during TKI therapy. To definitively confirm this 
assumption, it will be important to further evaluate whether the 
emergence of innate CD8(+) T cells in terms of both number and 
functional potential is closely related to long-term remission after 
treatment discontinuation.
To date, in mice, even though the effector functions of innate/
memory CD8(+) T cells have been extensively tested in vitro, 
their actual role during immune responses remains poorly docu-
mented. Testing the in  vivo response following infection with 
the bacteria Listeria monocytogenes, innate/memory CD8(+) 
T cells were found to have a protective function (5, 6). As far 
as immune responses against tumors are concerned, only in 
lymphodepleted mice, does there exist evidence that these cells 
can enhance response to tumors (30–33). Given our findings, it 
remains to be directly determined, using experimental tumor 
models in mice, whether or not innate CD8(+) T cells exert 
protective functions.
The precise mechanisms for the generation and/or main-
tenance of innate CD8(+) T cells in humans remain to be 
determined. In the mouse, a key role in Eomes upregulation 
has been attributed to PLZF-expressing T cells. Similarly, our 
data in peripheral blood show a close correlation between the 
levels of Eomes in innate CD8(+) T cells and of PLZF in iNKT 
cells. Moreover, expression of PLZF and Eomes in iNKT cells 
and innate CD8(+) T cells, respectively, were both found to 
be reduced in patients at CML diagnosis, and reversed after 
disease remission, as were innate CD8(+) T cells in terms of 
both number and functions. Taken together, these findings are 
consistent with the existence of a PLZF-dependent mechanism 
in humans, similar to that reported in mice. It remains to 
FigUre 4 | (a) Positive correlation between invariant natural killer T (iNKT) cell promyelocytic leukemia zinc finger (PLZF) expression and innate CD8 T cell 
Eomes expression. Eomes and PLZF expression were analyzed in innate CD8(+) T cells and iNKT cells, respectively, among peripheral blood mononuclear cells 
(PBMCs) by flow cytometry ex vivo after cellular permeabilization. Eomes expression and PLZF were analyzed after gating on killer cell Ig-like receptor (KIR)/
NKG2A(+) CD8(+) CD3(+) cells and 6B11(+) CD3(+) cells, respectively. Mean fluorescence intensity (MFI) values are expressed relative to that of isotype control. 
Data from healthy donor (n = 5), chronic myeloid leukemia (CML)-CP (n = 6), and CML-imatinib mesylate (n = 3) were pooled. The MFI of PLZF-expressing iNKT 
[6B11(+) CD3(+)] cells correlate positively with MFI of Eomes expression on innate CD8(+) T [KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+)] cells (correlation 
Spearman test; n = 14, r = 0.7275, p = 0.0043). (B–D) Innate CD8(+) T cells depend on IL-4 for homeostasis/expansion. PBMCs from five HDs were cultured 
for 7 days with IL-4 or medium alone (not stimulated, NS) and then analyzed by flow cytometry ex vivo after cellular permeabilization for innate CD8(+) T cells. 
Frequency (B), absolute cell number (c), and Eomes MFI (D) (mean ± SEM) of CD3(+) CD8(+) cells among total live PBMCs (left) and KIR/NKG2A(+) Eomes(+) 
CD8(+) CD3(+) cells among CD3(+) CD8(+) cells (right) are shown. Statistical significance was determined by the one-tailed Wilcoxon non-parametric test. 
*p < 0.05; **p < 0.01.
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determine whether, as in mice, PLZF-expressing T cells, espe-
cially iNKT cells, promote the development of blood peripheral 
innate T CD8(+) T cells by providing IL-4. In accordance with 
this view, we recently demonstrated a functional deficiency of 
IL-4 production by iNKT cells in CML patients at diagnosis and 
its partial restoration in patients having achieved remission after 
TKI therapy (22).
Further investigations are required to elucidate the exact 
mechanisms accounting for the deficiency of innate CD8(+) 
T cells at diagnosis and the beneficial effect of TKI therapy on 
this pool of cells. Nonetheless, from our data, it is tempting to 
speculate that the dysfunctions of innate CD8(+) T cells in CML 
patients at diagnosis that are remedied by TKI therapy originate 
from antigen APC-dependent dysfunctions, which in turn might 
contribute to iNKT cell deficiencies. This hypothesis arises from 
our recent findings showing that BCR-ABL from CML myeloid 
DCs mediates iNKT-cell immune subversion by downregulat-
ing cell-surface CD1d expression (27). Another non-exclusive 
mechanism may involve IL-15, which is required for maintenance 
not only of conventional memory CD8(+) T cells (34, 35) but also 
innate/memory CD8(+) T cells (32, 36). Indeed, CD8α(+) DC 
trans-presentation of IL-15 contributes to development of innate-
like CD8(+) T cells in the periphery (37). For these reasons, the 
possible existence of a deficit in IL-15 expression and/or in IL-15 
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trans-presentation by mDCs from CML-CP patients is deserving 
of special attention.
All in all, by revealing an iNKT/innate CD8(+) T-cell axis 
with expected physiopathological relevance in CML, our findings 
should enhance understanding of the T cell components restored 
in CML treatment that contribute to disease control. From a more 
general standpoint, our study underscores the potential role of 
innate CD8(+) T cells against tumors in conjunction with iNKT 
cells and may contribute significantly to our understanding of 
the role of these innate T cell subsets in the development of 
protective immunity in humans.
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